Cita APA

Piha-Paul, S., Geva, R., Tan, T., Lim, D. W., Hierro Carbó, C., & Doi, T. (2021). First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.

Citación estilo Chicago

Piha-Paul, Sarina, Ravit Geva, Tira Tan, Darren Wan-Teck Lim, Cinta Hierro Carbó, y Toshikiko Doi. First-in-human Phase I/Ib Open-label Dose-escalation Study of GWN323 (anti-GITR) As a Single Agent and in Combination With Spartalizumab (anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas. 2021.

Cita MLA

Piha-Paul, Sarina, et al. First-in-human Phase I/Ib Open-label Dose-escalation Study of GWN323 (anti-GITR) As a Single Agent and in Combination With Spartalizumab (anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas. 2021.